Your email has been successfully added to our mailing list.

×
0 0 0 0 0.0248343949044585 0.0254777070063694 0.0254777070063694 0.0254777070063694
Stock impact report

Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha]

Immunic, Inc. (IMUX) 
Company Research Source: Seeking Alpha
Immunic up 26% after hours on encouraging IMU-838 data Thinly traded micro cap Immunic (NASDAQ: IMUX 26% interim analysis CALDOSE-1 The data showed activity at the lowest dose (10 mg) and tolerability at the highest dose (45 mg). The trial will continue with all three dosing arms (30 mg is the other). The expansion of the potentially effective dose range will increase the target enrollment to ~240 from 195, expected to be completed in H2 2020. Topline data should be available in Q1 2021. The company says IMU-838 Show less Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IMUX alerts
Opt-in for
IMUX alerts

from News Quantified
Opt-in for
IMUX alerts

from News Quantified